<DOC>
	<DOC>NCT02758769</DOC>
	<brief_summary>Examine the effectiveness and safety of the abatacept administration in biologic-naïve rheumatoid arthritis patients who have moderate disease activity despite treatments with conventional synthetic disease modified anti-rheumatic drugs.</brief_summary>
	<brief_title>Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice Settings</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Patients with RA who meet the 2010 American College of Rheumatology / European League against Rheumatisms (ACR/EULAR) RA Classification Criteria Patients with RA with a moderate disease activity (SDAI: &gt; 11 and 26) Biologicnaive patients with treatment history csDMARDs Patients who meet the following criteria by hematological examination: Peripheral white blood cell count: 4,000/mm3 Peripheral lymphocyte count: 1,000/mm3 Blood βDglucan negative Patients who understand the investigator's explanation of study procedures and have given voluntary written consent to participate in this study Patients initiated with abatacept at per their physician's therapeutic decision Past history of hypersensitivity to the components of the abatacept preparation Disease complications from a comorbidity Active infectious disease Been judged by the investigator or the coinvestigator as being inappropriate Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>